Ibex Medical Analytics (Ibex), the global pioneer in AI-powered pathology, today celebrates 10 years of clinical innovation. Ahead of the European Congress of Pathology (ECP) 2026, Ibex also launches Ibex Breast Lymph Node*, rounding out the industry’s most comprehensive, end-to-end Breast AI Suite, offering laboratories a unified workflow that seamlessly transitions from primary biopsy and excision review1-4 to IHC pre-ordering5 and IHC scoring across biopsies, resections and Lymph Nodes.

Over ten years of continuous innovation, Ibex has established itself as the leading provider of clinical-grade AI applications. Ibex has spent a decade developing highly accurate and robustly validated AI solutions. Ibex is the only independent computational pathology vendor with FDA clearance and holds numerous CE-IVDR certified solutions. Today, the company’s platform is backed by an extensive body of clinical evidence – demonstrated across numerous multi-center trials and peer-reviewed publications, and is proven daily in routine clinical practice at hundreds of live sites worldwide, analyzing 2.4 million slides per year with AI.

Clinical maturity is driving accelerated commercial scale, as healthcare networks are transitioning from fragmented, single-use tools to end-to-end, clinical-grade workflows. AI adoption is expanding rapidly to combat severe pathologist shortages, mounting workloads and the surge in testing needed to support targeted therapies, ensuring that despite these systemic pressures, patient care remains the absolute priority and diagnostic quality is never compromised. Consequently, existing Ibex customers are expanding their installations while new labs are deploying their first applications. This global expansion, accelerated by our trusted commercial partners, is highlighted by large strategic collaborations in the USA, a wave of recent deployments across Italy, and growing momentum in the UK and wider Europe.

The Complete Breast AI Suite: From Workflow Automation to Primary Diagnosis & Reporting

Hosted on the next-generation Ibex 4 platform, the complete Breast AI Suite offers a fully integrated digital pathway that streamlines every step of the diagnostic process. The unified solution spans high-performance biopsy and excision review (H&E)1-4, accurate interpretation across our fully CE-IVDR-certified breast IHC panel6-8 (including HER2, ER, PR and Ki67), and metastasis detection with the newly released Ibex Lymph Node*. Crucially, the AI platform optimizes daily operations with automated workflow features5, including streamlined reporting and the automatic pre-ordering of IHCs, minimizing manual administrative tasks and accelerating diagnostic turnaround times.

A Vision Realized: Pioneering Clinical Pathology and Expanding into Biopharma

“When we founded Ibex in 2016, AI in pathology was a frontier concept met with skepticism,” said Yossi Mossel, Co-founder, and President of Ibex Medical Analytics. “Our goal was to build highly accurate, clinical-grade technology that pathologists could trust in their daily work. Today, seeing our algorithms running live in labs across the globe, backed by the industry’s strongest clinical evidence, is the truest validation of that original vision. As we look ahead, we are leveraging this proven, clinical-grade foundation to expand our partnerships within biopharma – allowing us to accelerate biomarker discovery and regulatory clearance to bring targeted therapies to patients faster. We have spent ten years proving that AI doesn’t just assist pathologists; it elevates the entire standard of care for precision oncology.”

“With the full breast suite now completed, we are delivering on our promise to provide a truly comprehensive diagnostic support platform for breast cancer pathology,” said Yair Heller, CEO of Ibex Medical Analytics. “Ibex 4 is designed to transform the diagnostic journey, enabling pathologists to work with unparalleled efficiency and ensuring that every patient receives the most accurate and personalized insights possible. We look forward to continually expanding our AI pipeline to address even more critical laboratory workflows.”

To learn more about the complete Breast AI Suite, explore our unmatched clinical evidence, and celebrate Ibex’s 10-year journey of digital pathology innovation, visit Booth #330 at ECP 2026 or visit: https://ibex-ai.com/breast/.

About Ibex Medical Analytics

Ibex is the global leader in clinical-grade AI for pathology, with hundreds of clinically deployed solutions and partnerships spanning top pharmaceutical organizations, life-science companies, reference laboratories, and digital pathology vendors. Ibex collaborates with leading biopharma teams to accelerate biomarker development and commercialization using AI-powered IHC scoring algorithms and our existing commercial network, backed by an ISO 13485-compliant QMS.

Ibex Breast is IVDR certified and includes the Ibex platform solutions for Breast H&E (biopsies and excisions) and Breast IHC (HER2, ER, PR, Ki67). The Ibex platform includes solutions that are CE-marked (including CE-IVDR certified solutions) and registered with MHRA in the UK, TGA in Australia, ANVISA in Brazil, AMAR in Israel & Swissmedic in Switzerland. It includes a solution that is FDA-cleared and others that are RUO in the United States.

For additional company information, please visit https://ibex-ai.com/ and follow us on LinkedIn and X.

*Lymph node is currently for Research Use Only

References:

  1. Sandbank et al. NPJ Breast Cancer 2022; 8:129.

  2. Tahir et al. Clin Breast Cancer. 2025; :S1526-8209(25)00083-7.

  3. Vecsler et al. Virchows Arch. 2025;487(Suppl 1):PS-01-038

  4. Canas-Marques et al. Virchows Arch. 2025 Sep;487(Suppl 1):OFP-05-007

  5. Deman et al. (2026), Histopathology, https://doi.org/10.1111/his.70181

  6. Krishnamurthy et al., JCO Precis Oncol 2024; 8, e2400353.

  7. Vecsler et al. Clin Cancer Res 2026; 32 (4_Supplement): PD11-10

  8. Vincent-Salomon et al. Lab Invest 2026, 106 (3): 104501

 

Media gallery

About The Author
Business Wire